FDA Grants Label Expansion to J&J's Tremfya in Ulcerative ColitisZacks Investment Research • 09/12/24
Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravisGlobeNewsWire • 09/12/24
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel diseasePRNewsWire • 09/11/24
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)PRNewsWire • 09/10/24
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancerPRNewsWire • 09/08/24
Johnson & Johnson, Flex to Keynote at MEDevice Silicon Valley on the Future of Technology and Security in Patient CareAccesswire • 09/05/24
Johnson & Johnson (JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/04/24
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 09/03/24